Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.
作者信息
Leng Siyang, Lentzsch Suzanne, Shen Yanhan, Tsai Wei-Yann, Wright Jason Dennis, Hershman Dawn Lauryn, Neugut Alfred I
机构信息
a Department of Medicine, College of Physicians and Surgeons , Columbia University , New York , NY , USA.
b Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons , Columbia University , New York , NY , USA.
出版信息
Leuk Lymphoma. 2018 Oct;59(10):2465-2469. doi: 10.1080/10428194.2018.1429605. Epub 2018 Feb 2.
Abstract
摘要
相似文献
1
Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.蛋白酶体抑制剂治疗的骨髓瘤患者中带状疱疹预防措施的使用及影响
Leuk Lymphoma. 2018 Oct;59(10):2465-2469. doi: 10.1080/10428194.2018.1429605. Epub 2018 Feb 2.
2
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.来那度胺治疗多发性骨髓瘤患者中水痘带状疱疹病毒感染（包括复杂的水痘带状疱疹病毒和单纯疱疹病毒感染）的发生率、风险因素和预防措施。
Ann Hematol. 2014 Mar;93(3):479-84. doi: 10.1007/s00277-013-1951-6. Epub 2013 Dec 7.
3
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?预防性抗病毒药物可能有助于预防骨髓瘤中水痘带状疱疹病毒的再激活，但它们安全吗？
J Oncol Pharm Pract. 2010 Dec;16(4):266-8. doi: 10.1177/1078155209350374. Epub 2009 Dec 4.
4
[Risk Factors and the Effect of Antiviral Prophylaxis for Herpes Zoster in Multiple Myeloma Patients].[多发性骨髓瘤患者带状疱疹的危险因素及抗病毒预防效果]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):171-175. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.027.
5
Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.在接受硼替佐米治疗的多发性骨髓瘤患者中，用中药板蓝根进行水痘-带状疱疹病毒预防。
J Altern Complement Med. 2011 Nov;17(11):985-6. doi: 10.1089/acm.2011.0386.
6
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.硼替佐米治疗患者中连续、每日、口服、超低剂量 200mg 阿昔洛韦预防带状疱疹事件的疗效：一项回顾性研究报告。
Jpn J Clin Oncol. 2011 Jul;41(7):876-81. doi: 10.1093/jjco/hyr063. Epub 2011 May 25.
7
Bortezomib and bilateral herpes zoster.硼替佐米与双侧带状疱疹
Acta Dermatovenerol Alp Pannonica Adriat. 2012;21(1):21-2.
8
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.接受硼替佐米或沙利度胺化疗的多发性骨髓瘤患者的水痘带状疱疹病毒特异性细胞介导免疫与带状疱疹的发生
J Clin Virol. 2015 Dec;73:64-69. doi: 10.1016/j.jcv.2015.10.018. Epub 2015 Oct 24.
9
10
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.硼替佐米治疗的骨髓瘤患者中，低剂量阿昔洛韦预防带状疱疹有效：来自韩国多发性骨髓瘤工作组（KMMWP）回顾性研究的报告。
Jpn J Clin Oncol. 2011 Mar;41(3):353-7. doi: 10.1093/jjco/hyq194. Epub 2010 Oct 14.
引用本文的文献
1
Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an <I>ad hoc</I> Italian expert panel.针对血液系统疾病或造血干细胞移植受者中带状疱疹感染的个体化预防：来自意大利专家组的一份立场文件。
Haematologica. 2024 Nov 1;109(11):3496-3504. doi: 10.3324/haematol.2023.284417.
2
Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.硼替佐米为基础的三联方案序贯来那度胺治疗初诊多发性骨髓瘤患者的疗效和安全性分析。
Clin Exp Med. 2023 Sep;23(5):1573-1580. doi: 10.1007/s10238-022-00879-0. Epub 2022 Sep 12.
3
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.实体瘤和血液系统恶性肿瘤患者疱疹病毒再激活的管理：德国血液学和肿瘤医学学会传染病工作组（AGIHO）关于单纯疱疹病毒 1 型、单纯疱疹病毒 2 型和水痘带状疱疹病毒指南的更新。
Ann Hematol. 2022 Mar;101(3):491-511. doi: 10.1007/s00277-021-04746-y. Epub 2022 Jan 7.
4
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.考虑患者、疾病和治疗相关因素，为复发/难治性多发性骨髓瘤（RRMM）患者选择合适的治疗方法。
Cancers (Basel). 2021 Aug 26;13(17):4320. doi: 10.3390/cancers13174320.
5
Evidence-based supportive care in multiple myeloma.多发性骨髓瘤的循证支持治疗
J Community Hosp Intern Med Perspect. 2020 Aug 2;10(4):313-317. doi: 10.1080/20009666.2020.1771124.
6
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.新型口服药物时代的套细胞淋巴瘤的治疗管理。
Ann Pharmacother. 2020 Sep;54(9):879-898. doi: 10.1177/1060028020909117. Epub 2020 Feb 20.
本文引用的文献
1
Herpes zoster risk after 21 specific cancers: population-based case-control study.21种特定癌症后的带状疱疹风险：基于人群的病例对照研究
Br J Cancer. 2017 Jun 6;116(12):1643-1651. doi: 10.1038/bjc.2017.124. Epub 2017 May 2.
2
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.接受硼替佐米或沙利度胺化疗的多发性骨髓瘤患者的水痘带状疱疹病毒特异性细胞介导免疫与带状疱疹的发生
J Clin Virol. 2015 Dec;73:64-69. doi: 10.1016/j.jcv.2015.10.018. Epub 2015 Oct 24.
3
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.多发性骨髓瘤与感染：一项基于9253例多发性骨髓瘤患者的人群研究。
Haematologica. 2015 Jan;100(1):107-13. doi: 10.3324/haematol.2014.107714. Epub 2014 Oct 24.
4
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.硼替佐米诱导和维持治疗新诊断多发性骨髓瘤患者：随机 III 期 HOVON-65/GMMG-HD4 试验结果。
J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16.
5
Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.阿昔洛韦预防接受硼替佐米治疗的多发性骨髓瘤患者水痘带状疱疹病毒再激活：100例患者的回顾性分析
J Support Oncol. 2012 Jul-Aug;10(4):155-9. doi: 10.1016/j.suponc.2011.10.006. Epub 2012 Jan 4.
6
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.硼替佐米联合地塞米松优于长春新碱联合多柔比星联合地塞米松作为新诊断多发性骨髓瘤患者自体造血干细胞移植前的诱导治疗：IFM 2005-01 期 III 期试验结果。
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
7
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.国际骨髓瘤工作组关于不适用于标准高剂量化疗联合自体干细胞移植的多发性骨髓瘤患者的管理指南。
Leukemia. 2009 Oct;23(10):1716-30. doi: 10.1038/leu.2009.122. Epub 2009 Jun 4.
8
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.阿昔洛韦预防接受硼替佐米治疗的多发性骨髓瘤患者水痘带状疱疹病毒（带状疱疹）再激活。
Cancer. 2009 Jan 1;115(1):229-32. doi: 10.1002/cncr.24006.
9
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.硼替佐米联合美法仑和泼尼松用于多发性骨髓瘤的初始治疗。
N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.
10
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.在III期APEX研究中对接受硼替佐米治疗患者的带状疱疹事件分析。
J Clin Oncol. 2008 Oct 10;26(29):4784-90. doi: 10.1200/JCO.2007.14.9641. Epub 2008 Aug 18.
Zotero 插件